PCDH15

Across TCGA pan-cancer cohorts, PCDH15 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PCDH15’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PCDH15 RNA is repressed in tumor relative to normal tissue. In most cancer types PCDH15 is over-expressed in tumor, although a few such as LUAD and KIRC show the opposite, repressed pattern.

LUAD, KIRC, and LUSC are the cancer types where PCDH15 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCDH15 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.983	<.001	11	view →
KIRC	Male	All	−0.330	<.001	10	view →
LUSC	All	III,IV	−0.994	<.001	9	view →
KIRP	All	III,IV	−0.518	<.001	9	view →
COAD	All	All	−0.019	<.001	7	view →
KICH	All	All	−0.179	<.001	6	view →
BRCA	All	II,III,IV	−0.022	<.001	6	view →
THCA	All	II,III,IV	−0.023	.003	5	view →
HNSC	Female	IV	+0.041	.007	3	view →
STAD	Male	II,III,IV	−0.017	.024	2	view →
LIHC	Female	All	+0.011	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PCDH15–LUAD

Open the LUAD breakdown →